IFAM
DNLI icon

Institutional & Family Asset Management’s Denali Therapeutics DNLI Stock Holding History

Institutional & Family Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11
Closed -$236 – 743
2023
Q4 		$236 Hold
11
– – ﹤0.01% 691
2023
Q3 		$227 Hold
11
– – ﹤0.01% 697
2023
Q2 		$325 Hold
11
– – ﹤0.01% 713
2023
Q1 		$253 Hold
11
– – ﹤0.01% 707
2022
Q4 		$306 Buy
11
+5
+83% +$149 ﹤0.01% 686
2022
Q3 		$0 Hold
6
– – ﹤0.01% 719
2022
Q2 		$0 Hold
6
– – ﹤0.01% 737
2022
Q1 		$0 Buy
+6
New +$206 ﹤0.01% 789
2021
Q4 		– Sell
-6
Closed – – 830
2021
Q3 		$0 Sell
6
-4
-40% -$225 ﹤0.01% 920
2021
Q2 		$1K Hold
10
– – ﹤0.01% 881
2021
Q1 		$1K Sell
10
-6
-38% -$402 ﹤0.01% 853
2020
Q4 		$1K Buy
+16
New +$967 ﹤0.01% 829

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Institutional & Family Asset Management's DNLI Position: Q1 2024 in Review

Institutional & Family Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 11 shares — an estimated $236 sold.

Institutional & Family Asset Management first reported a position in DNLI in Q4 2020 and held it in 12 quarters. The position peaked at $1K in Q2 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Institutional & Family Asset Management reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Institutional & Family Asset Management sold 11 Denali Therapeutics shares in Q1 2024, an estimated $236.
  • Institutional & Family Asset Management first reported a position in Denali Therapeutics in Q4 2020 and held it in 12 quarters.
  • Institutional & Family Asset Management's Denali Therapeutics position peaked at $1K in Q2 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Institutional & Family Asset Management's 13F filing for Q1 2024, filed 8 May 2024.